Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $137.4 million.

  • Adma Biologics' Total Non-Current Liabilities fell 13.22% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year decrease of 13.22%. This contributed to the annual value of $139.3 million for FY2024, which is 28.03% down from last year.
  • Per Adma Biologics' latest filing, its Total Non-Current Liabilities stood at $137.4 million for Q3 2025, which was down 14.15% from $160.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Total Non-Current Liabilities ranged from a high of $199.8 million in Q3 2022 and a low of $120.4 million during Q2 2021.
  • For the 3-year period, Adma Biologics' Total Non-Current Liabilities averaged around $172.6 million, with its median value being $187.7 million (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 51.26% in 2022, then slumped by 30.30% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Total Non-Current Liabilities stood at $134.7 million in 2021, then skyrocketed by 45.63% to $196.1 million in 2022, then decreased by 1.32% to $193.6 million in 2023, then declined by 28.03% to $139.3 million in 2024, then dropped by 13.22% to $137.4 million in 2025.
  • Its Total Non-Current Liabilities was $137.4 million in Q3 2025, compared to $160.1 million in Q2 2025 and $137.1 million in Q1 2025.